CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesBenzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein–ligand crystallographyStructural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapyFragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerChk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibitionDynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention.Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabineComparative analysis of radiosensitizers for K-RAS mutant rectal cancersSelective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells.PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.Checkpoint kinase inhibitors: a patent review (2009 - 2010).Checkpoint control and cancer.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression.Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics.Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion.Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.Report and Application of a Tool Compound Data Set.Directing the use of DDR kinase inhibitors in cancer treatment.ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy
P2860
Q26745686-939C4DE4-8C19-491C-8503-C8A162598831Q26768679-78006362-9240-4557-B917-985F45502D6CQ26776513-CB6458CE-B0DA-4BC0-BB6B-356DA13B3B77Q26864870-E90C4049-A3BC-415E-9EBA-905619EC482FQ27674450-DBE1956A-311B-4EC6-AE9D-AFE4ADF1C02DQ27674646-FF272A1D-C55D-492B-A267-456CCE563207Q27678684-4EDA4009-43A7-49A1-B64F-F1E503D4EB4EQ28066320-1E937BED-D242-4E41-BBCB-0B874CFBE5C8Q28396027-7FB2228E-93B5-445C-BE89-CF27E064AFBBQ31090728-CC541EEC-189B-40E0-AD48-04F157548A90Q34154791-F7109453-4D02-4ADA-A05C-47864595FB18Q35070685-DF967382-E10E-4D81-96F8-D53E555D6354Q35737519-F7E0936A-AD74-494D-8F1A-CE88F09869CAQ36054290-B5A4EA2E-48C8-4A1D-8FE7-FE076F53ED35Q36328196-000DDD93-D480-430B-84D2-02987F97AB10Q36413938-118B34C1-D867-4FFA-AED7-4282EEF84582Q36740692-EC1F24AC-E1FE-4C24-AB59-2E1752DBA937Q36771796-0288C1BB-CF23-4D8F-BDD6-6E58A69DEEBCQ36792626-F65A63BA-3955-4A4B-8A74-140DCADCC6B1Q37877694-04F58007-D43E-4E2D-A11A-FB68CB53A643Q37941374-19426CD5-AAA4-435B-AD06-E6A2244B1DB8Q38683171-8C49F2C5-C224-48D7-ADB0-E7DF1128A612Q38702556-693E9CA3-7C69-40E0-8B06-E1F3033762C5Q38790328-B36F1B81-483E-4C58-BC04-121AD721C6D6Q38844919-836A1F06-7A85-48CC-BFE0-F1F09656CEDAQ39354733-715A282B-1E46-40FB-9EE5-365837ED1DF2Q40105033-EDD52F16-46BE-49C7-BA8A-99D5346ECCD4Q41125698-2FE12190-78D0-4F9C-BF1E-36B1157E88F5Q42632659-CF927331-53BE-4AC7-9B7B-3987CAADB012Q47648532-94CD49E2-FBF8-42B2-9192-E193DE357D21Q47687840-2B0586E1-EA8E-4884-B55A-0BF655AC0E81Q52316521-10742970-7E71-4370-95B9-D463FA6652AAQ55004657-6D45E405-923F-423F-B78F-B65EB39D714BQ55478403-76814E08-F86A-45FE-9490-55E708AE01EAQ58773614-FCBAE9AE-A4E5-4C37-83B2-9DBE7FAC6891
P2860
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@en
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@nl
type
label
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@en
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@nl
prefLabel
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@en
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@nl
P2093
P2860
P1433
P1476
CCT241533 is a potent and sele ...... totoxicity of PARP inhibitors.
@en
P2093
Antony W Oliver
Ian Collins
John J Caldwell
Katherine J Boxall
Laurence H Pearl
Laurent Antoni
Michael I Walton
Michelle D Garrett
Paul D Eve
Victoria E Anderson
P2860
P304
P356
10.1158/0008-5472.CAN-10-1252
P407
P577
2011-01-01T00:00:00Z